Abraxis BioScience Announces Dates for 2007 Year-End Financial Results and Investor Conference Call

LOS ANGELES--(BUSINESS WIRE)--Abraxis BioScience, Inc. (NASDAQ: ABII), an integrated, global biopharmaceutical company, today announced it will release its 2007 fourth quarter and year-end financial results after the market closes on Monday, March 31, 2008. The company also said that senior management will host an investor conference call the next day, Tuesday, April 1, 2008, at 8:30 a.m. PT/11:30 a.m. ET to review the company’s financial results.

The conference call will be available to interested parties through a live audio webcast at www.abraxisbio.com and www.earnings.com.

About Abraxis BioScience, Inc.

Abraxis BioScience is a fully integrated global biotechnology company dedicated to the discovery, development and delivery of next-generation therapeutics and core technologies that offer patients safer and more effective treatments for cancer and other critical illnesses. The company’s portfolio includes the world’s first and only protein-based nanoparticle chemotherapeutic compound (ABRAXANE^®), which is based on the company’s proprietary tumor targeting technology known as the nab™ platform. The first FDA approved product to use this nab platform, ABRAXANE^®, was launched in 2005 for the treatment of metastatic breast cancer. Abraxis trades on the Nasdaq Global Market under the symbol ABII. For more information about the company and its products, please visit www.abraxisbio.com.